Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy

Medicina

Volumn 47, Issue 9, 2011, Pages 520-525

  Drobniene, Monika ^a   Ciceniene, Audrone ^a   Želviene, Terese Pipiriene ^a   Grigiene, Ruta ^a   Lachej, Nadežda ^a   Steponavičiene, Laura ^a   Aleknavičius, Eduardas ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Erlotinib; Lung adenocarcinoma; Targeted therapy

Indexed keywords

EID: 84856659147     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina47090069     Document Type: Article

References (16)

1. Smailytė G, Aleknavičienė B. Vėžys Lietuvoje 2009 metais. Vėžio registras, Vėžio kontrolės ir profi laktikos centras, Vilniaus universiteto Onkologijos institutas. 2011. p. 9-39.
2. Cicėnas S, Kurtinaitis J, Smailytė G. Outcome and treatment strategy in female lung cancer: a single institution experience. Adv Med Sci 2010;55(2):273-80.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
4. Rapp E, Pater JL, Wilan A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1998;6:633-41.
5. DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008. p. 936.
6. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
7. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298:70-82.
8. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003;4:397-406.
9. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and effi cacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-21.
10. Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations. J Thorac Oncol 2010;5:99-104.
11. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-75.
12. Felip E, Gridelli C, Baas P, Rosell R, Stahel R; Panel Members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, fi rst-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011;22:1507-19.
13. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
14. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79.
15. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-12.
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.